PubMed Daily Triage Digest — 2026-07-21

Run ID: 2026-07-21-attempt1-20260721T090000Z
Run Timestamp: 2026-07-21T09:00:00Z
Articles Identified: 25 total (HIGH: 11, MEDIUM: 13, LOW: 1)
Date Window: 2026-07-20 to 2026-07-21 (CRDT)

Topic Coverage Summary

HIGH Priority Articles (11)

1. Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4xCD3) ImmTAC targeting MAGE-A4-expressing malignancies.

PMID: 42476725 | Journal: J Immunother Cancer | Date: 2026-07-20 | Score: 10/10 Authors: Sweis RF, Melero I, Davar D, Garralda E, Hamid O et al. DOI: https://doi.org/10.1136/jitc-2025-014638 Study Design: Phase I/II clinical trial, multicenter ⚗️ Clinical Trial Key Finding: IMC-C103C (ImmTAC TCR bispecific targeting MAGE-A4xCD3) demonstrated antitumor activity with manageable safety across multiple MAGE-A4-positive solid tumor histologies in this Phase 1/2 dose-escalation/expansion study. Summary: This multicenter Phase 1/2 trial evaluated IMC-C103C across MAGE-A4-positive solid tumors, establishing dose-dependent antitumor activity with a safety profile consistent with T cell-redirecting therapies. Results position IMC-C103C as a promising first-in-class ImmTAC agent with activity across multiple solid tumor types defined by shared MAGE-A4 expression. Triage Reason: First-in-class ImmTAC TCR bispecific Phase I/II multicenter trial in MAGE-A4+ solid tumors; mechanistically novel; J Immunother Cancer indexed MEDLINE; directly actionable intelligence for immuno-oncology pipeline. Topics: novel_therapeutics, immunotherapy, TCR_bispecific, MAGE-A4, clinical_trial, solid_tumors

2. Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.

PMID: 42476727 | Journal: J Immunother Cancer | Date: 2026-07-20 | Score: 10/10 Authors: Ullern A, Garborg KK, Chauhan SK, Holm K, Bang C et al. DOI: https://doi.org/10.1136/jitc-2026-015122 Study Design: Phase II clinical trial ⚗️ Clinical Trial Key Finding: Fecal microbiota transplantation from immune responder donors proved safe and showed preliminary antitumor efficacy signals in solid cancer patients refractory to immune checkpoint inhibitors, establishing proof-of-concept for microbiome-based ICI sensitization. Summary: The MITRIC Phase II trial assessed FMT from immune responder donors in ICI-resistant solid cancer patients, evaluating whether gut microbiome reconstitution could restore immunotherapy sensitivity. Results demonstrated favorable safety and early efficacy signals, supporting continued investigation of microbiome modulation to overcome ICI resistance. Triage Reason: Phase II RCT-grade clinical trial of FMT to overcome ICI resistance; novel microbiome-immunotherapy axis; high unmet need; J Immunother Cancer. Topics: novel_therapeutics, immunotherapy, FMT, ICI_resistance, clinical_trial, solid_tumors, microbiome

3. AI-assisted decision support for sickle cell disease severity stratification using routine blood tests: a systematic review and meta-analysis.

PMID: 42477641 | Journal: BMC Med Inform Decis Mak | Date: 2026-07-20 | Score: 9/10 Authors: Ali NT, H Mehdi MA, Abdullah RS, Ali GS, Ali HM et al. DOI: https://doi.org/10.1186/s12911-026-03679-8 Study Design: Systematic review and meta-analysis Key Finding: AI and ML models using routine CBC and standard hematological parameters can reliably stratify SCD severity with high pooled diagnostic accuracy, validating CBC-based clinical decision support for sickle cell disease management. Summary: This systematic review and meta-analysis synthesized AI/ML evidence for SCD severity stratification using routine blood tests, addressing the unmet need for accessible risk tools in resource-limited settings. Pooled findings support CBC-based AI as a practical, low-cost decision support adjunct for SCD severity assessment. Triage Reason: Directly relevant to T2 CBC-ML topic; systematic review + meta-analysis provides highest evidence level; SCD is a high-unmet-need rare hematologic disease; validates routine CBC as AI input for clinical decision support. Topics: cbc_ml_hematology, sickle_cell_disease, machine_learning, AI, clinical_decision_support, hematology

4. Allogeneic hematopoietic cell transplantation from haploidentical donors with total body irradiation versus chemo-based regimens for adult AML patients in first complete remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

PMID: 42477157 | Journal: Bone Marrow Transplant | Date: 2026-07-20 | Score: 8/10 Authors: Maffini E, Labopin M, Raiola AM, Blaise D, Bramanti S et al. DOI: https://doi.org/10.1038/s41409-026-02988-w Study Design: Multicenter retrospective registry analysis (EBMT) Key Finding: EBMT registry analysis of adult AML CR1 patients undergoing haploidentical HCT found distinct relapse and survival differences between TBI-based and chemotherapy-based conditioning, providing real-world evidence for conditioning selection in the absence of randomized data. Summary: This large EBMT multicenter registry analysis compared TBI-based versus chemotherapy-based conditioning in adult AML CR1 patients receiving haploidentical donor transplantation, addressing a critical clinical decision point lacking RCT evidence. The dataset enables granular assessment of relapse, NRM, and OS tradeoffs across conditioning modalities. Triage Reason: EBMT multicenter registry data directly informing AML haploidentical SCT conditioning; large real-world dataset; directly relevant to T1 hematologic malignancies watchlist. Topics: hematologic_malignancies, AML, haploidentical_transplant, EBMT, conditioning, TBI

5. Anti-BNLF2b antibody for accurate diagnosis of nasopharyngeal carcinoma: a prospective comparative study.

PMID: 42477590 | Journal: BMC Cancer | Date: 2026-07-21 | Score: 8/10 Authors: Huang B, Yang L, Luo X, Dai W, Chen H et al. DOI: https://doi.org/10.1186/s12885-026-16523-z Study Design: Prospective comparative study Key Finding: Anti-BNLF2b EBV antibody demonstrated high diagnostic accuracy for NPC in prospective head-to-head comparison with established EBV serological markers, supporting its utility as a non-invasive blood-based NPC biomarker. Summary: This prospective comparative study evaluated anti-BNLF2b antibody as a novel EBV-specific serum biomarker for NPC diagnosis versus established anti-VCA and anti-EBNA markers. The antibody showed superior or equivalent diagnostic performance, offering potential as an accessible screening tool in NPC-endemic regions. Triage Reason: Prospective biomarker validation for NPC liquid diagnosis; directly relevant to early cancer detection watchlist; NPC has high unmet need for non-invasive diagnosis especially in Southeast Asian/East Asian populations. Topics: early_cancer_detection, nasopharyngeal_carcinoma, EBV, blood_biomarker, serology, cancer_diagnosis

6. Unraveling missing variants through target capture-based long-read sequencing in autosomal recessive disorders.

PMID: 42477409 | Journal: Eur J Hum Genet | Date: 2026-07-20 | Score: 8/10 Authors: Lee JS, Ryu KS, Lee H, Lim H, Youn S et al. DOI: https://doi.org/10.1038/s41431-026-02197-5 Study Design: Prospective diagnostic validation study Key Finding: Target capture-based long-read sequencing identified previously missed pathogenic variants (structural variants, repeat expansions, complex rearrangements) in patients with suspected autosomal recessive disorders unresolved by standard short-read NGS, substantially improving molecular diagnostic yield. Summary: This study applied target capture-based long-read sequencing to a cohort of AR disorder patients with negative or inconclusive short-read NGS results, demonstrating resolution of complex variants invisible to conventional approaches. Improved diagnostic yields have direct implications for rare disease molecular diagnosis, variant counseling, and reproductive decision-making. Triage Reason: Long-read sequencing for missing variants in AR disorders directly addresses rare disease diagnostic gap; EJHG publication; multicenter clinical dataset; clinically actionable for rare disease genomics pipeline. Topics: rare_diseases, long_read_sequencing, autosomal_recessive, precision_genomics, diagnostic_yield

7. Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial.

PMID: 42477619 | Journal: BMC Cancer | Date: 2026-07-21 | Score: 8/10 Authors: Chen H, Jiang T, Wang H, Zheng J, Du B et al. DOI: https://doi.org/10.1186/s12885-026-16491-4 Study Design: Single-center exploratory randomized controlled trial ⚗️ Clinical Trial Key Finding: In RAS wild-type mCRC after first-line failure, cetuximab-irinotecan rechallenge showed comparable or superior efficacy and potentially better tolerability versus regorafenib in this exploratory RCT, supporting rechallenge as a precision oncology strategy in molecularly selected patients. Summary: This single-center exploratory RCT compared cetuximab-irinotecan rechallenge versus standard third-line regorafenib in RAS WT mCRC, examining whether anti-EGFR rechallenge can overcome acquired resistance. Results suggest rechallenge is a viable precision approach with potential tolerability advantages, warranting further investigation in larger multicenter trials. Triage Reason: Randomized trial in mCRC rechallenge strategy; precision oncology context (RAS WT selection); directly relevant to T5 and T6 watchlists; exploratory but provides RCT-level evidence for a growing precision oncology approach. Topics: precision_oncology, colorectal_cancer, cetuximab, rechallenge, RAS_wild_type, clinical_trial, EGFR

8. Analysis of the efficacy and safety of the IVD/EM maintenance regimen as post-remission treatment for adult patients with T-cell lymphoblastic lymphoma/leukemia.

PMID: 42475939 | Journal: Leuk Res | Date: 2026-07-15 | Score: 8/10 Authors: Xie Z, Song Y, Zhang Y, Wang D, Wang K et al. DOI: https://doi.org/10.1016/j.leukres.2026.108282 Study Design: Retrospective cohort analysis Key Finding: The IVD/EM (ifosfamide/vincristine/dexamethasone/etoposide/methotrexate) maintenance regimen demonstrated efficacy and acceptable toxicity as post-remission treatment for adult T-cell lymphoblastic lymphoma/leukemia, contributing evidence to the sparse post-remission literature for this aggressive malignancy. Summary: This retrospective cohort study evaluated the IVD/EM maintenance regimen in adult T-ALL/TLL patients following induction remission, reporting disease-free survival, overall survival, and toxicity endpoints in a real-world cohort. Results support IVD/EM as an active and manageable post-remission strategy for this challenging hematologic malignancy with limited comparative data. Triage Reason: Post-remission maintenance strategy for T-ALL/TLL published in Leukemia Research; sparse literature on optimal maintenance for this aggressive malignancy; directly addresses T1 hematologic malignancies watchlist (T-cell lineage). Topics: hematologic_malignancies, T-ALL, lymphoblastic_lymphoma, maintenance_therapy, treatment_outcomes, leukemia

9. Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation.

PMID: 42476726 | Journal: J Immunother Cancer | Date: 2026-07-20 | Score: 7/10 Authors: Miller DM, Merkin RD, Kaufman HL, Gupta SG, Wolkow N et al. DOI: https://doi.org/10.1136/jitc-2026-015029 Study Design: Retrospective Bayesian causal analysis Key Finding: Bayesian causal analysis in cutaneous SCC found that early response to frontline PD-1 immunotherapy predicts long-term outcomes and supports response-guided de-escalation strategies, potentially reducing cumulative toxicity without compromising efficacy. Summary: The FIRST study used Bayesian causal methods to analyze dose intensity, early benefit, and de-escalation potential in cutaneous SCC patients receiving frontline immune checkpoint inhibitors. Findings suggest early responders may safely tolerate treatment de-escalation, informing personalized immunotherapy duration and reducing toxicity burden. Triage Reason: Innovative Bayesian causal analysis methodology applied to immunotherapy optimization in cutaneous SCC; J Immunother Cancer; actionable for personalized immunotherapy duration research. Topics: novel_therapeutics, immunotherapy, cutaneous_SCC, PD-1, treatment_optimization, Bayesian_methods

10. NOD1/2 signaling in macrophages drives adaptive immune resistance in cancer.

PMID: 42476973 | Journal: Signal Transduct Target Ther | Date: 2026-07-16 | Score: 7/10 Authors: Wei X, Yang L, Wang Y, Wang K, Wang D et al. DOI: https://doi.org/10.1038/s41392-026-02758-6 Study Design: Experimental mechanistic study (in vitro and in vivo) Key Finding: NOD1/2 innate immune PRR signaling in tumor-associated macrophages promotes adaptive immune resistance by suppressing effector T cell responses, identifying a novel innate-adaptive immune axis in cancer immune evasion targetable to enhance anti-tumor immunity. Summary: This mechanistic study demonstrated that NOD1/2 receptor signaling in tumor-associated macrophages within the TME drives immune resistance by suppressing effector T cells through immunosuppressive mediator upregulation, revealing a previously underappreciated innate immune checkpoint. Published in Signal Transduction and Targeted Therapy, findings suggest NOD1/2 as a tractable therapeutic target to enhance immunotherapy responses. Triage Reason: Novel NOD1/2-macrophage immune resistance mechanism; published in high-impact Signal Transduct Target Ther; mechanistically actionable for next-generation immunotherapy target intelligence. Topics: novel_therapeutics, tumor_microenvironment, macrophage, NOD1_NOD2, immune_resistance, innate_immunity

11. Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

PMID: 42477505 | Journal: Liver Int | Date: 2026-08 | Score: 7/10 Authors: Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M et al. DOI: https://doi.org/10.1111/liv.70803 Study Design: Multicenter real-world retrospective study (48 Japanese clinics) Key Finding: Baseline DCP (des-gamma-carboxyprothrombin) level differentially modified survival response to atezolizumab-bevacizumab versus durvalumab-tremelimumab in unresectable HCC, positioning DCP as a potential predictive biomarker for first-line immunotherapy selection. Summary: Using real-world data from the RELPEC Study Group and 48 Japanese HCC clinics, this study identified baseline DCP as a biomarker that modifies the relative effectiveness of two approved first-line HCC immunotherapy combinations. DCP-guided treatment selection could improve HCC outcomes by matching patients to the most effective combination immunotherapy regimen. Triage Reason: Large real-world multicenter biomarker-guided immunotherapy selection study in unresectable HCC; DCP as differential predictive biomarker for two approved regimens; high clinical relevance for immuno-oncology treatment selection intelligence. Topics: novel_therapeutics, HCC, immunotherapy, biomarker, atezolizumab, durvalumab, DCP, treatment_selection

MEDIUM Priority Articles (13)

1. Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a m...

PMID: 42477572 | Journal: BMC Cancer | Score: 6/10 | Design: Multicentre retrospective real-world cohort Key Finding: Real-world UK Midlands data for atezolizumab-bevacizumab in unresectable HCC showed effectiveness consistent with IMbrave150 trial outcomes, confirming generalizability to European clinical practice.

2. Early identification of cirrhosis risk in type 2 diabetes using the Fibrosis-4 index: evidence from ...

PMID: 42477634 | Journal: BMC Endocr Disord | Score: 6/10 | Design: Large retrospective U.S. cohort study Key Finding: FIB-4 index applied in a large U.S. T2D cohort enabled early identification of patients at risk for cirrhosis, with FIB-4 thresholds detecting progressive hepatic fibrosis before clinical symptoms, su...

3. Dual residual risk of lipid and inflammation: a prospective analysis of RCII on hypertension inciden...

PMID: 42477565 | Journal: BMC Cardiovasc Disord | Score: 6/10 | Design: Prospective cohort analysis (CHARLS + UK Biobank) Key Finding: The RCII composite index integrating residual inflammatory and lipid risk independently predicted hypertension incidence and major adverse cardiovascular outcomes in both Chinese (CHARLS) and UK Bioba...

4. Association of cholesterol, high-density lipoprotein, and glucose index and modified indices in pred...

PMID: 42477562 | Journal: BMC Cardiovasc Disord | Score: 6/10 | Design: Nationwide prospective cohort study Key Finding: Composite CHG (cholesterol-HDL-glucose) and modified indices predicted CVD incidence independently across CKM syndrome stages 0-3 in a nationwide Chinese cohort, providing practical lipid-glycemic com...

5. Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion...

PMID: 42477458 | Journal: Oncogene | Score: 6/10 | Design: Experimental mechanistic study (in vitro and in vivo) Key Finding: SRSF2-mediated alternative splicing of hnRNPD promotes isoform switching that drives PD-L1 upregulation and immune evasion in gallbladder cancer, revealing a splicing-regulated checkpoint mechanism wi...

6. Recent breakthroughs in blood-based biomarkers of Alzheimer disease: opportunities and challenges in...

PMID: 42476554 | Journal: Age Ageing | Score: 6/10 | Design: Narrative review Key Finding: Recent blood-based AD biomarkers (plasma p-tau217, p-tau181, Abeta42/40 ratio, NfL) show high diagnostic accuracy comparable to CSF and PET in appropriately selected older adult populations, though ch...

7. Genome-wide assessment of rare protein-coding variants identifies associations with non-syndromic cl...

PMID: 42477406 | Journal: Eur J Hum Genet | Score: 6/10 | Design: Genome-wide rare variant association study Key Finding: Genome-wide rare protein-coding variant analysis identified novel genetic associations with non-syndromic cleft lip with or without palate, expanding the mutational landscape beyond established common...

8. Capability of multiparametric MRI to detect diabetic nephropathy in high-risk patients with type 2 d...

PMID: 42477596 | Journal: BMC Med Imaging | Score: 6/10 | Design: Prospective preliminary study Key Finding: Multiparametric MRI combining DWI, DCE, T1 mapping, and T2* mapping detected diabetic nephropathy with good diagnostic accuracy in high-risk T2D patients, offering a non-invasive alternative to renal ...

9. Prohibitin 2 is a key regulator of T cell proliferation, differentiation, and effector functions in ...

PMID: 42477470 | Journal: Commun Biol | Score: 6/10 | Design: Experimental in vivo mechanistic study (conditional knockout Key Finding: Prohibitin 2 (PHB2), a mitochondrial inner membrane protein, is an essential regulator of T cell proliferation, effector subset differentiation, and cytokine production in vivo, with T cell-specific P...

10. Beyond immune checkpoint blockade: T cell engagers and antibody-drug conjugates in cancer and autoim...

PMID: 42476268 | Journal: Biochem Pharmacol | Score: 5/10 | Design: Narrative review Key Finding: T cell engagers (BiTEs, ImmTACs, DART molecules) and antibody-drug conjugates represent the most promising non-checkpoint immunotherapy modalities with expanding clinical stage pipelines across divers...

11. BCMA-Targeted Therapy Enables Combined Haploidentical Stem Cell and Kidney Transplantation in a High...

PMID: 42476317 | Journal: Am J Transplant | Score: 5/10 | Design: Case report Key Finding: BCMA-targeted therapy was used to deplete alloantibody-producing plasma cells in a highly sensitized patient, enabling successful combined haploidentical stem cell and kidney transplantation—a novel e...

12. Unusual B-Cell Lymphoproliferative Disorders Co-Occurring With Nonmelanoma Skin Cancer: Report of Th...

PMID: 42476618 | Journal: J Cutan Pathol | Score: 4/10 | Design: Case series (3 cases) Key Finding: Three cases of B-cell lymphoproliferative disorders concurrent with nonmelanoma skin cancer reveal potential clonal relationships and shared pathogenetic mechanisms, illustrating diagnostic complexity...

13. Association and diagnostic efficacy of waist-to-height ratio with glycemic control in young and midd...

PMID: 42477670 | Journal: BMC Endocr Disord | Score: 4/10 | Design: Cross-sectional diagnostic study Key Finding: Waist-to-height ratio (WHtR) showed significant association with glycemic control status and diagnostic utility for identifying poor glycemic control in young and middle-aged adults with early-onset T...

LOW Priority Articles (1)

1. Identification and characterization of the virome in cell-free DNA from peripheral blood of pregnant...

PMID: 42477451 | Journal: Sci Rep | Score: 3/10 | Reason: False positive in T3 early cancer detection search (cfDNA keyword match); describes pregnancy virome characterization without cancer relevance; LOW pr

Pipeline Notes

• Outstanding signal today: Two Phase I/II clinical trials in novel immunotherapy (IMC-C103C TCR bispecific, MITRIC FMT trial) are the day's top finds (both score 10/10).
• T2 (CBC+ML): Only 1 result in window but it is a systematic review + meta-analysis directly validating AI-assisted SCD stratification using routine blood tests — strong anchor article.
• T6 (Novel Therapeutics): Strongest topic day with 5 HIGH articles including 2 clinical trials. NOD1/2 macrophage immune resistance (Signal Transduct Target Ther) is the most mechanistically novel basic science find.
• T7 (Cardiometabolic): No GLP-1/SGLT2 trial data in today's window. FIB-4 for cirrhosis risk in T2D (BMC Endocr Disord) is the most actionable cardiometabolic catch.
• False positives noted: T1 search captured GBD 2023 road injuries (PMID 42476159) via false MDS keyword match; T3 search captured pregnancy virome study (PMID 42477451) via cfDNA match; T3 captured osteoporosis screening review (PMID 42477227) via screening keyword.
• Schema version: 1.3 | Attempt: 1 of 3

Generated by OpenClaw Friday at 2026-07-21T09:00:00Z